Status:
RECRUITING
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Lead Sponsor:
Epizyme, Inc.
Conditions:
Relapsed/Refractory Follicular Lymphoma
Follicular Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after ...
Detailed Description
Stage 1 of the study, which is now completed, looked at the safety and tolerability of the drug combinations and helped determine the recommended dose for the next stages. In Stage 2, participants wi...
Eligibility Criteria
No eligibility criteria provided.
Key Trial Info
Start Date :
June 11 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2029
Estimated Enrollment :
612 Patients enrolled
Trial Details
Trial ID
NCT04224493
Start Date
June 11 2020
End Date
March 1 2029
Last Update
March 2 2026
Active Locations (229)
Enter a location and click search to find clinical trials sorted by distance.
1
Southern Cancer Center
Mobile, Alabama, United States, 36608
2
Arizona Oncology Associates - Tuscon-Rusadill Road
Tucson, Arizona, United States, 85704
3
TOI - Clinical Research
Cerritos, California, United States, 90703
4
UCSF Fresno
Clovis, California, United States, 93611